Tripeptides, particularly collagen-derived tripeptides, have been investigated for their potential to support cartilage health and repair cartilage damage. Scientific interest stems from the fact that cartilage is primarily composed of collagen, and peptides derived from collagen hydrolysates may stimulate extracellular matrix synthesis in chondrocytes, the cells responsible for maintaining cartilage tissue.

Several in vitro and animal studies indicate that orally administered collagen peptides, including tripeptides such as Gly-Pro-Hyp, can be absorbed and reach joint tissues, where they may promote collagen synthesis and inhibit cartilage degradation. For example, research published in the journal Osteoarthritis and Cartilage (2017) demonstrated that specific collagen tripeptides improved cartilage matrix production and reduced inflammatory markers in chondrocytes. Human clinical trials are more limited but some randomized controlled trials have reported modest improvements in joint pain and function in individuals with osteoarthritis after supplementation with collagen peptides.

However, while the evidence suggests biological plausibility and some benefit, it is not yet definitive. Most clinical studies involve small sample sizes, and not all use isolated tripeptides but rather broader collagen hydrolysates. Meta-analyses suggest a positive trend but call for larger, long-term studies to confirm efficacy and clarify mechanisms. Thus, the use of tripeptides for cartilage damage is scientifically plausible and supported by preliminary evidence, but not yet established as a standard of care.